Prot #ACR-368-201/GOG-3082: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSign

Project: Research project

Project Details

StatusActive
Effective start/end date3/24/23 → 3/24/26

Funding

  • Gynecologic Oncology Group (Prot #ACR-368-201/GOG-3082)
  • Acrivon Therapeutics, Inc (Prot #ACR-368-201/GOG-3082)